Supply chain issues have plagued the U.S. economy since the COVID-19 pandemic shut down much of the world. Now, with the Russian invasion of Ukraine on top of a new surge in China, different areas of the supply chain are being tested.
States will see a significant reduction in shipments of COVID-19 monoclonal antibody treatments from the federal government beginning March 21 as the White House’s request for $15.6 billion in pandemic funding stalls in Congress, ABC News reported.
The FDA is returning to normal facility inspection operations, which were significantly disrupted by the COVID-19 pandemic, according to a March 21 report from The New York Times.
Several hundred providers of Evusheld, a COVID-19 antibody treatment for immunocompromised, were removed from a federal dataset March 16, making it even more difficult to locate the therapy, Kaiser Health News reported March 17.
A new $350 million medical manufacturing facility producing nitrile gloves is set to be built in Baltimore County, Maryland, according to a March 16 news release from the manufacturer.
The images and reports from the war in Ukraine have moved several health systems to action, donating their own medical supplies and medicines to be sent to the war-torn nation.